Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 139 Carcinoma, Intraductal, Noninfiltrating 8 Neoplasm Metastasis 6 Breast Carcinoma In Situ 5 Breast Neoplasms, Male 4 Breast Diseases 4 Arthralgia 4 Triple Negative Breast Neoplasms 3 Ovarian Neoplasms 3 Endometrial Neoplasms 3 Advanced Breast Cancer 3 Neoplasms 2 Breast Cancer Metastatic 2 Solid Tumor 1 Sexual Dysfunctions, Psychological 1 Sexual Dysfunction, Physiological 1 Seizures 1 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Pain 1 Osteoporosis 1 Obesity 1 Muscle Neoplasms 1 Multiple Endocrine Neoplasia Type 1 1 Locoregional Recurrence 1 Invasive Breast Cancer 1 Hypogonadism 1 Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1

Interventions

venetoclax 1 pyrotinib 1 pertuzumab 1 penpulimab 1 palbociclib 1 dalpiciclib 1 anlotinib 1 Tretinoin 1 Trastuzumab 1 Ropivacaine 1 Radiosurgery 1 Propofol 1 Patient Reported Outcome Measures 1 Paclitaxel 1 Ondansetron 1 Morphine 1 Letrozole 1 Induction Chemotherapy 1 Fulvestrant 1 Etoricoxib 1 Docetaxel 1 Diagnostic Imaging 1 Carboplatin 1 Capecitabine 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Neoplasm Female × Anastrozole × Clear all

NCT04113863 2025-12-18

ATRA

Mario Negri Institute for Pharmacological Research

Phase 2 Terminated

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon ⚡